drugset / Trial / NCT05661955
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma
Timeline
- Start
- 2023-01-09
- Primary completion
- 2025-05-27
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gimistotug | Monoclonal antibody | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |